CA2536069C - Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire - Google Patents
Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire Download PDFInfo
- Publication number
- CA2536069C CA2536069C CA002536069A CA2536069A CA2536069C CA 2536069 C CA2536069 C CA 2536069C CA 002536069 A CA002536069 A CA 002536069A CA 2536069 A CA2536069 A CA 2536069A CA 2536069 C CA2536069 C CA 2536069C
- Authority
- CA
- Canada
- Prior art keywords
- green
- light
- porphyrin
- choroidal
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000004032 porphyrins Chemical class 0.000 title claims description 88
- 238000003745 diagnosis Methods 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 45
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 238000002428 photodynamic therapy Methods 0.000 abstract description 42
- 239000000975 dye Substances 0.000 abstract description 29
- 206010028980 Neoplasm Diseases 0.000 abstract description 28
- 238000002583 angiography Methods 0.000 abstract description 4
- 208000010642 Porphyrias Diseases 0.000 abstract 3
- 239000000906 photoactive agent Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 48
- 230000006378 damage Effects 0.000 description 31
- 210000001525 retina Anatomy 0.000 description 21
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 description 15
- 210000003161 choroid Anatomy 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 230000001427 coherent effect Effects 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 11
- 230000001678 irradiating effect Effects 0.000 description 11
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000013534 fluorescein angiography Methods 0.000 description 10
- 210000001210 retinal vessel Anatomy 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 239000003504 photosensitizing agent Substances 0.000 description 7
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002962 histologic effect Effects 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 241000288906 Primates Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 3
- 206010057430 Retinal injury Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000002488 pyknotic effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 230000002165 photosensitisation Effects 0.000 description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004233 retinal vasculature Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 208000016623 Choroid neoplasm Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 206010055666 Retinal neovascularisation Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000002588 choroid cancer Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940035564 duration Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000001316 polygonal cell Anatomy 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1994/002639 WO1995024930A1 (fr) | 1994-03-14 | 1994-03-14 | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire |
CA2185644A CA2185644C (fr) | 1994-03-14 | 1994-03-14 | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2185644A Division CA2185644C (fr) | 1994-03-14 | 1994-03-14 | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2536069A1 CA2536069A1 (fr) | 1995-09-21 |
CA2536069C true CA2536069C (fr) | 2008-06-03 |
Family
ID=22242340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2185644A Expired - Lifetime CA2185644C (fr) | 1994-03-14 | 1994-03-14 | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire |
CA002536069A Expired - Lifetime CA2536069C (fr) | 1994-03-14 | 1994-03-14 | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2185644A Expired - Lifetime CA2185644C (fr) | 1994-03-14 | 1994-03-14 | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6813694A (fr) |
CA (2) | CA2185644C (fr) |
WO (1) | WO1995024930A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
JP3845469B2 (ja) | 1996-02-21 | 2006-11-15 | 明治製菓株式会社 | 眼底の新生血管の閉塞に用いる投与剤 |
US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
NZ331977A (en) * | 1996-03-26 | 2000-07-28 | Pharmacyclics Inc | Texaphyrin in photodynamic therapy of pigment-related lesions |
US6043237A (en) * | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
IL130246A0 (en) * | 1996-12-11 | 2000-06-01 | Pharmacyclics Inc | Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy |
US6022526A (en) * | 1997-07-30 | 2000-02-08 | Pharmacyclics, Inc. | Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
US6351663B1 (en) | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
US6944493B2 (en) | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
AU7106400A (en) * | 1999-09-10 | 2001-04-10 | Akorn, Inc. | Fluorescent dye angiography and dye-enhanced photocoagulation |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US20020049247A1 (en) * | 2000-01-12 | 2002-04-25 | Chen James C. | Novel treatment for eye disease |
AU2001234979B2 (en) * | 2000-02-10 | 2006-07-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
AU2006203034B2 (en) * | 2000-02-10 | 2006-09-07 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US7753943B2 (en) | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
CA2437557C (fr) * | 2001-02-06 | 2012-07-24 | Qlt Inc. | Therapie photodynamique a debit de fluence reduit permettant de traiter la neovascularisation choroidienne due a l'amd |
IL161327A0 (en) * | 2001-11-09 | 2004-09-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
CA2500877A1 (fr) | 2002-10-03 | 2004-04-15 | Light Sciences Corporation | Systeme et procede d'excitation d'elements photosensibles des tissus de l'oeil |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171749A (en) * | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5214036A (en) * | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
-
1994
- 1994-03-14 CA CA2185644A patent/CA2185644C/fr not_active Expired - Lifetime
- 1994-03-14 WO PCT/US1994/002639 patent/WO1995024930A1/fr active Application Filing
- 1994-03-14 AU AU68136/94A patent/AU6813694A/en not_active Abandoned
- 1994-03-14 CA CA002536069A patent/CA2536069C/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU6813694A (en) | 1995-10-03 |
CA2185644A1 (fr) | 1995-09-21 |
WO1995024930A1 (fr) | 1995-09-21 |
CA2185644C (fr) | 2011-04-12 |
CA2536069A1 (fr) | 1995-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5707986A (en) | Angiographic method using green porphyrins in primate eyes | |
US6225303B1 (en) | Use of green porphyrins to treat neovasculature in the eye | |
CA2536069C (fr) | Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire | |
EP0894009B1 (fr) | Vision amelioree par therapie photodynamique de l'oeil | |
EP0799055B1 (fr) | Visualisation ou traitement selectif et non invasif du systeme vasculaire | |
Peyman et al. | Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2) | |
JP2003519670A (ja) | 眼疾患の新規処置 | |
EP1262179A1 (fr) | Therapie photodynamique destinee a traiter selectivement des neovaisseaux dans le tissu du fond de l'oeil | |
US6524330B1 (en) | Method of ocular treatment | |
Moshfeghi et al. | Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies | |
Moshfeghi et al. | Fluorescence properties of a hydrophilic sensitizer in pigmented rats, rabbits, and monkeys | |
Levy et al. | Use Of Green Porphyrinsto Treat Neovasculature In The Eyes | |
AU705100C (en) | Improved vision through photodynamic therapy of the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140314 |